Search Results

You are looking at 81 - 90 of 110 items for :

  • "aromatase inhibitor" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Jennifer Barsky Reese, Lauren A. Zimmaro, Sharon L. Bober, Kristen Sorice, Elizabeth Handorf, Elaine Wittenberg, Areej El-Jawahri, Mary Catherine Beach, Antonio C. Wolff, Mary B. Daly, Brynna Izquierdo, and Stephen J. Lepore

main ideas that all patients should receive a discussion of sexual issues, but then certain groups of patients, including those on aromatase inhibitors and ovarian suppression, require special care due to the severity and abruptness of sexual problems

Full access

Leslie R. Schover, Ying Yuan, Bryan M. Fellman, Evan Odensky, Pamela E. Lewis, and Paul Martinetti

aromatase inhibitors, 7 direct genital damage from pelvic radiation therapy, 8 - 10 and genital graft-versus-host disease. 11 Urinary and fecal incontinence often lead to avoidance of sexual contact. 12 The recent NCCN Clinical Practice Guidelines in

Full access

Mathias Kvist Mejdahl, Birgitte Goldschmidt Mertz, Pernille Envold Bidstrup, and Kenneth Geving Andersen

treatment consisted of tamoxifen or aromatase inhibitor according to hormonal receptor status and menopausal status. Statistical Analyses Statistical analyses were performed with SPSS Statistics for Windows, Version 19.0 (IBM Corp, Armonk, NY

Full access

Kathleen Harnden and Kimberly Blackwell

/ABCSG XX) . Presented at the 2013 San Antonio Breast Cancer Symposium ; December 13, 2013 ; San Antonio, Texas . 25. Llombart A Frassoldati A Paija O . Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal

Full access

Rowan T. Chlebowski, Aaron K. Aragaki, and Garnet L. Anderson

oophorectomy or aromatase inhibitor use with established breast cancer. However, with additional postintervention follow-up, a seemingly paradoxical situation arose. Despite the decreasing HR trend seen during the early postintervention period, the summary

Full access

Courtney P. Williams, Andres Azuero, Kelly M. Kenzik, Maria Pisu, Ryan D. Nipp, Smita Bhatia, and Gabrielle B. Rocque

effects of aromatase inhibitors versus tamoxifen: the patients’ perspective . Am J Surg 2006 ; 192 : 496 – 498 . 16978958 10.1016/j.amjsurg.2006.06.018 25. Vogel CL , Cobleigh MA , Tripathy D , . First-line Herceptin monotherapy in metastatic

Full access

Parijatham S. Thomas

(SERMs) and aromatase inhibitors (AIs) for the prevention of breast cancer. The Breast Cancer Prevention Trial (BCPT) evaluated 13,388 women aged ≥35 years with an elevated risk of breast cancer randomized to tamoxifen daily for 5 years or placebo

Full access

chemotherapy. Methods: This study used the MarketScan and PharMetrics claims databases (January 1, 2002–June 30, 2014) to identify postmenopausal women with HR+/HER2− mBC who failed a nonsteroidal aromatase inhibitor and later initiated a new line of therapy

Full access

Wui-Jin Koh, Nadeem R. Abu-Rustum, Sarah Bean, Kristin Bradley, Susana M. Campos, Kathleen R. Cho, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Shari Damast, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Suzanne George, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Stefanie Ueda, Emily Wyse, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone

–6 months). 40 , 157 Progesterone-based therapy has been shown to provide some benefit with low toxicity in patients with low-grade tumors. 158 Tamoxifen with alternating megestrol 159 and aromatase inhibitors has also been used. 160 – 163 For suspected

Full access

Robert W. Carlson, Susan J. Moench, M. Elizabeth H. Hammond, Edith A. Perez, Harold J. Burstein, D. Craig Allred, Charles L. Vogel, Lori J. Goldstein, George Somlo, William J. Gradishar, Clifford A. Hudis, Mohammad Jahanzeb, Azadeh Stark, Antonio C. Wolff, Michael F. Press, Eric P. Winer, Soonmyung Paik, Britt-Marie Ljung, and for the NCCN HER2 Testing in Breast Cancer Task Force

amplification and response to either tamoxifen or aromatase inhibitors. 85 , 88 – 91 Despite inconsistent data, however, HER2 status has been, and may continue to be, considered in clinical decision-making involving hormonal therapies. 92 Trastuzumab with